| Q101234689 | A Preliminary Study on Machine Learning-Based Evaluation of Static and Dynamic FET-PET for the Detection of Pseudoprogression in Patients with IDH-Wildtype Glioblastoma |
| Q43259949 | Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide |
| Q33417361 | Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial |
| Q36705933 | Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial |
| Q56967323 | DNA methylation-based classification of ependymomas in adulthood: implications for diagnosis and treatment |
| Q48451808 | Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET. |
| Q42391408 | Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET imaging for the detection of checkpoint inhibitor-related pseudoprogression in melanoma brain metastases |
| Q48090038 | Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma |
| Q49026174 | Erratum to: Gliomatosis cerebri: no evidence for a separate brain tumor entity |
| Q44153742 | Gliomatosis cerebri: molecular pathology and clinical course |
| Q40401765 | Gliomatosis cerebri: no evidence for a separate brain tumor entity |
| Q48157598 | Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study |
| Q41045513 | Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[18F]fluoroethyl)-L-Tyrosine PET. |
| Q38905080 | Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma |
| Q34604010 | Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide |
| Q48342416 | MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial |
| Q40465928 | Migratory neural stem cells for improved thymidine kinase-based gene therapy of malignant gliomas. |
| Q47827397 | Multicenter pilot study of radio-chemotherapy as first-line treatment for adults with medulloblastoma (NOA-07). |
| Q48418407 | Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. |
| Q40497236 | SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo |